Keyphrases
Heart Failure with Preserved Ejection Fraction (HFpEF)
78%
Polypill
69%
Heart Failure
68%
Guideline-directed Medical Therapy
58%
Patients with Heart Failure
56%
Fixed-dose Combination
41%
World Health Organization
40%
Fixed-dose Combination Therapy
37%
India
37%
Atherosclerotic Cardiovascular Disease (ASCVD)
32%
Quality Improvement Intervention
31%
Acute Heart Failure
27%
Kerala
27%
Risk Factors
25%
Trivandrum
24%
Organizational Trust
24%
South India
24%
Wellcome Trust
24%
Patent Information
24%
Expert Group
24%
Law
24%
Wald
24%
ASCVD Risk
24%
Sex Differences
23%
Hospital-based
17%
Essential Medicines
16%
Cardiovascular Mortality
16%
Interrupted Time Series
16%
Mixed-methods Study
16%
Clinical Outcomes
15%
Process of Care
14%
At Discharge
14%
CARE Measure
13%
Randomized Controlled Trial
13%
Cardiovascular Risk
13%
Heart Failure Patients
13%
Blood Pressure Lowering
11%
Heart Failure Care
11%
Cardiovascular Disease
11%
Confidence Interval
11%
Beta-blockers
10%
Meta-analysis
10%
Etiology
10%
Hospital Readmission
9%
All-cause Mortality
9%
Reduced Ejection Fraction
9%
Heart Failure Risk
9%
Middle-income Countries
9%
Low-income Countries
9%
Healthcare Professionals
8%
Medicine and Dentistry
Congestive Heart Failure
100%
Combination Therapy
75%
Polypill
72%
Heart Failure with Reduced Ejection Fraction
53%
Quality Improvement
34%
Acute Decompensated Heart Failure
27%
Cardiovascular System
24%
Medicine
24%
Systematic Review
24%
Time Series Analysis
16%
Atherosclerosis
16%
Cardiovascular Disease
15%
Randomized Controlled Trial
12%
Low and Middle Income Countries
11%
Sex Difference
11%
Heart Failure with Preserved Ejection Fraction
11%
Cardiovascular Disease Risk Factor
9%
Meta-Analysis
9%
Myocardial Disease
8%
Cross Sectional Study
8%
Essential Medicines
8%
Household
8%
Medicare
8%
Canagliflozin
8%
Health Care Provider
8%
Mediator
8%
Acute Coronary Syndrome
8%
Diuretics
8%
Randomized Clinical Trial
8%
Ejection Fraction
7%
Clinical Trial
6%
Mineralocorticoid Antagonist
6%
All Cause Mortality
6%
Logistic Regression Analysis
5%
Beta Adrenergic Receptor Blocking Agent
5%
Renin Angiotensin Aldosterone System
5%